Submit Feedback
Learn more about AbbVie's Revenue by Segment and Revenue by Region.
Check out competitors to AbbVie in a side-by-side comparison.
Explore additional financial metrics for AbbVie.
| 2015 | 22859000000.00 |
|---|---|
| 2016 | 25638000000.00 |
| 2017 | 28216000000.00 |
| 2018 | 32753000000.00 |
| 2019 | 33266000000.00 |
| 2020 | 45804000000.00 |
| 2021 | 56197000000.00 |
| 2022 | 58054000000.00 |
| 2023 | 54318000000.00 |
| 2024 | 56334000000.00 |
| 2025 | 61160000000.00 |
| Mar 2016 | 5958000000.00 |
|---|---|
| Jun 2016 | 6452000000.00 |
| Sep 2016 | 6432000000.00 |
| Dec 2016 | 6796000000.00 |
| Mar 2017 | 6538000000.00 |
| Jun 2017 | 6944000000.00 |
| Sep 2017 | 6995000000.00 |
| Dec 2017 | 7739000000.00 |
| Mar 2018 | 7934000000.00 |
| Jun 2018 | 8278000000.00 |
| Sep 2018 | 8236000000.00 |
| Dec 2018 | 8305000000.00 |
| Mar 2019 | 7828000000.00 |
| Jun 2019 | 8255000000.00 |
| Sep 2019 | 8479000000.00 |
| Dec 2019 | 8704000000.00 |
| Mar 2020 | 8619000000.00 |
| Jun 2020 | 10425000000.00 |
| Sep 2020 | 12902000000.00 |
| Dec 2020 | 13858000000.00 |
| Mar 2021 | 13010000000.00 |
| Jun 2021 | 13959000000.00 |
| Sep 2021 | 14342000000.00 |
| Dec 2021 | 14886000000.00 |
| Mar 2022 | 13538000000.00 |
| Jun 2022 | 14583000000.00 |
| Sep 2022 | 14812000000.00 |
| Dec 2022 | 15121000000.00 |
| Mar 2023 | 12225000000.00 |
| Jun 2023 | 13865000000.00 |
| Sep 2023 | 13927000000.00 |
| Dec 2023 | 14301000000.00 |
| Mar 2024 | 12310000000.00 |
| Jun 2024 | 14462000000.00 |
| Sep 2024 | 14460000000.00 |
| Dec 2024 | 15102000000.00 |
| Mar 2025 | 13343000000.00 |
| Jun 2025 | 15423000000.00 |
| Sep 2025 | 15776000000.00 |
| Dec 2025 | 16618000000.00 |
| Mar 2026 | 15002000000.00 |
| Jun 2026 | 16990000000.00 |
AbbVie's annual revenue was $61.16 B in fiscal year 2025.
AbbVie's quarterly revenue was $13.34 B(Q1: Mar 2025), $15.42 B(Q2: Jun 2025), $15.78 B(Q3: Sep 2025), $16.62 B(Q4: Dec 2025) in fiscal year 2025.
AbbVie's annual revenue was $56.33 B in fiscal year 2024.
AbbVie's quarterly revenue was $12.31 B(Q1: Mar 2024), $14.46 B(Q2: Jun 2024), $14.46 B(Q3: Sep 2024), $15.10 B(Q4: Dec 2024) in fiscal year 2024.
AbbVie's annual revenue was $54.32 B in fiscal year 2023.
AbbVie's quarterly revenue was $12.23 B(Q1: Mar 2023), $13.87 B(Q2: Jun 2023), $13.93 B(Q3: Sep 2023), $14.30 B(Q4: Dec 2023) in fiscal year 2023.
AbbVie's annual revenue was $58.05 B in fiscal year 2022.
AbbVie's quarterly revenue was $13.54 B(Q1: Mar 2022), $14.58 B(Q2: Jun 2022), $14.81 B(Q3: Sep 2022), $15.12 B(Q4: Dec 2022) in fiscal year 2022.
AbbVie's annual revenue was $56.20 B in fiscal year 2021.
AbbVie's quarterly revenue was $13.01 B(Q1: Mar 2021), $13.96 B(Q2: Jun 2021), $14.34 B(Q3: Sep 2021), $14.89 B(Q4: Dec 2021) in fiscal year 2021.
AbbVie's annual revenue was $45.80 B in fiscal year 2020.
AbbVie's quarterly revenue was $8.62 B(Q1: Mar 2020), $10.43 B(Q2: Jun 2020), $12.90 B(Q3: Sep 2020), $13.86 B(Q4: Dec 2020) in fiscal year 2020.
AbbVie's annual revenue was $33.27 B in fiscal year 2019.
AbbVie's quarterly revenue was $7.83 B(Q1: Mar 2019), $8.26 B(Q2: Jun 2019), $8.48 B(Q3: Sep 2019), $8.70 B(Q4: Dec 2019) in fiscal year 2019.
AbbVie's annual revenue was $32.75 B in fiscal year 2018.
AbbVie's quarterly revenue was $7.93 B(Q1: Mar 2018), $8.28 B(Q2: Jun 2018), $8.24 B(Q3: Sep 2018), $8.31 B(Q4: Dec 2018) in fiscal year 2018.
AbbVie's annual revenue was $28.22 B in fiscal year 2017.
AbbVie's quarterly revenue was $6.54 B(Q1: Mar 2017), $6.94 B(Q2: Jun 2017), $7.00 B(Q3: Sep 2017), $7.74 B(Q4: Dec 2017) in fiscal year 2017.
AbbVie's annual revenue was $25.64 B in fiscal year 2016.
AbbVie's quarterly revenue was $5.96 B(Q1: Mar 2016), $6.45 B(Q2: Jun 2016), $6.43 B(Q3: Sep 2016), $6.80 B(Q4: Dec 2016) in fiscal year 2016.
| 2015 | 0 |
|---|---|
| 2016 | +12.16 |
| 2017 | +10.06 |
| 2018 | +16.08 |
| 2019 | +1.57 |
| 2020 | +37.69 |
| 2021 | +22.69 |
| 2022 | +3.30 |
| 2023 | -6.44 |
| 2024 | +3.71 |
| 2025 | +8.57 |
| Q1: Mar 16 | 18.21 |
|---|---|
| Q2: Jun 16 | 17.84 |
| Q3: Sep 16 | 8.21 |
| Q4: Dec 16 | 6.19 |
| Q1: Mar 17 | 9.73 |
| Q2: Jun 17 | 7.63 |
| Q3: Sep 17 | 8.75 |
| Q4: Dec 17 | 13.88 |
| Q1: Mar 18 | 21.35 |
| Q2: Jun 18 | 19.21 |
| Q3: Sep 18 | 17.74 |
| Q4: Dec 18 | 7.31 |
| Q1: Mar 19 | -1.34 |
| Q2: Jun 19 | -0.28 |
| Q3: Sep 19 | 2.95 |
| Q4: Dec 19 | 4.80 |
| Q1: Mar 20 | 10.10 |
| Q2: Jun 20 | 26.29 |
| Q3: Sep 20 | 52.16 |
| Q4: Dec 20 | 59.21 |
| Q1: Mar 21 | 50.95 |
| Q2: Jun 21 | 33.90 |
| Q3: Sep 21 | 11.16 |
| Q4: Dec 21 | 7.42 |
| Q1: Mar 22 | 4.06 |
| Q2: Jun 22 | 4.47 |
| Q3: Sep 22 | 3.28 |
| Q4: Dec 22 | 1.58 |
| Q1: Mar 23 | -9.70 |
| Q2: Jun 23 | -4.92 |
| Q3: Sep 23 | -5.97 |
| Q4: Dec 23 | -5.42 |
| Q1: Mar 24 | 0.70 |
| Q2: Jun 24 | 4.31 |
| Q3: Sep 24 | 3.83 |
| Q4: Dec 24 | 5.60 |
| Q1: Mar 25 | 8.39 |
| Q2: Jun 25 | 6.65 |
| Q3: Sep 25 | 9.10 |
| Q4: Dec 25 | 10.04 |
| Q1: Mar 26 | 12.43 |
| Q2: Jun 26 | 10.16 |
AbbVieโs annual revenue increased +8.57% during fiscal year 2025 compared to 2024. It represents a growth of $4.83 B from $56.33 B (in 2024) to $61.16 B (in 2025).
AbbVieโs annual revenue increased +3.71% during fiscal year 2024 compared to 2023. It represents a growth of $2.02 B from $54.32 B (in 2023) to $56.33 B (in 2024).
AbbVieโs annual revenue decreased -6.44% during fiscal year 2023 compared to 2022. It represents a decline of $3.74 B from $58.05 B (in 2022) to $54.32 B (in 2023).
AbbVieโs annual revenue increased +3.30% during fiscal year 2022 compared to 2021. It represents a growth of $1.86 B from $56.20 B (in 2021) to $58.05 B (in 2022).
AbbVieโs annual revenue increased +22.69% during fiscal year 2021 compared to 2020. It represents a growth of $10.39 B from $45.80 B (in 2020) to $56.20 B (in 2021).
AbbVieโs annual revenue increased +37.69% during fiscal year 2020 compared to 2019. It represents a growth of $12.54 B from $33.27 B (in 2019) to $45.80 B (in 2020).
AbbVieโs annual revenue increased +1.57% during fiscal year 2019 compared to 2018. It represents a growth of $513.00 M from $32.75 B (in 2018) to $33.27 B (in 2019).
AbbVieโs annual revenue increased +16.08% during fiscal year 2018 compared to 2017. It represents a growth of $4.54 B from $28.22 B (in 2017) to $32.75 B (in 2018).
AbbVieโs annual revenue increased +10.06% during fiscal year 2017 compared to 2016. It represents a growth of $2.58 B from $25.64 B (in 2016) to $28.22 B (in 2017).
AbbVieโs annual revenue increased +12.16% during fiscal year 2016 compared to 2015. It represents a growth of $2.78 B from $22.86 B (in 2015) to $25.64 B (in 2016).
| Period | Revenue | Year-over-Year Change |
|---|---|---|
|
Get instant access to data, Sign up for free 
FY 2025
|
$61.16 B |
$4.83 B
8.57%
|
| Q4: Dec 25 | $16.62 B |
$1.52 B
10.04%
|
| Q3: Sep 25 | $15.78 B |
$1.32 B
9.1%
|
| Q2: Jun 25 | $15.42 B |
$961.00 M
6.65%
|
| Q1: Mar 25 | $13.34 B |
$1.03 B
8.39%
|
|
Get instant access to data, Sign up for free
FY 2024
|
$56.33 B |
$2.02 B
3.71%
|
| Q4: Dec 24 | $15.10 B |
$801.00 M
5.6%
|
| Q3: Sep 24 | $14.46 B |
$533.00 M
3.83%
|
| Q2: Jun 24 | $14.46 B |
$597.00 M
4.31%
|
| Q1: Mar 24 | $12.31 B |
$85.00 M
0.7%
|
|
Get instant access to data, Sign up for free
FY 2023
|
$54.32 B |
-$3.74 B
6.44%
|
| Q4: Dec 23 | $14.30 B |
-$820.00 M
5.42%
|
| Q3: Sep 23 | $13.93 B |
-$885.00 M
5.97%
|
| Q2: Jun 23 | $13.87 B |
-$718.00 M
4.92%
|
| Q1: Mar 23 | $12.23 B |
-$1.31 B
9.7%
|
|
Get instant access to data, Sign up for free
FY 2022
|
$58.05 B |
$1.86 B
3.3%
|
| Q4: Dec 22 | $15.12 B |
$235.00 M
1.58%
|
| Q3: Sep 22 | $14.81 B |
$470.00 M
3.28%
|
| Q2: Jun 22 | $14.58 B |
$624.00 M
4.47%
|
| Q1: Mar 22 | $13.54 B |
$528.00 M
4.06%
|
|
Get instant access to data, Sign up for free
FY 2021
|
$56.20 B |
$10.39 B
22.69%
|
| Q4: Dec 21 | $14.89 B |
$1.03 B
7.42%
|
| Q3: Sep 21 | $14.34 B |
$1.44 B
11.16%
|
| Q2: Jun 21 | $13.96 B |
$3.53 B
33.9%
|
| Q1: Mar 21 | $13.01 B |
$4.39 B
50.95%
|
|
Get instant access to data, Sign up for free
FY 2020
|
$45.80 B |
$12.54 B
37.69%
|
| Q4: Dec 20 | $13.86 B |
$5.15 B
59.21%
|
| Q3: Sep 20 | $12.90 B |
$4.42 B
52.16%
|
| Q2: Jun 20 | $10.43 B |
$2.17 B
26.29%
|
| Q1: Mar 20 | $8.62 B |
$791.00 M
10.1%
|
|
Get instant access to data, Sign up for free
FY 2019
|
$33.27 B |
$513.00 M
1.57%
|
| Q4: Dec 19 | $8.70 B |
$399.00 M
4.8%
|
| Q3: Sep 19 | $8.48 B |
$243.00 M
2.95%
|
| Q2: Jun 19 | $8.26 B |
-$23.00 M
0.28%
|
| Q1: Mar 19 | $7.83 B |
-$106.00 M
1.34%
|
|
Get instant access to data, Sign up for free
FY 2018
|
$32.75 B |
$4.54 B
16.08%
|
| Q4: Dec 18 | $8.31 B |
$566.00 M
7.31%
|
| Q3: Sep 18 | $8.24 B |
$1.24 B
17.74%
|
| Q2: Jun 18 | $8.28 B |
$1.33 B
19.21%
|
| Q1: Mar 18 | $7.93 B |
$1.40 B
21.35%
|
|
Get instant access to data, Sign up for free
FY 2017
|
$28.22 B |
$2.58 B
10.06%
|
| Q4: Dec 17 | $7.74 B |
$943.00 M
13.88%
|
| Q3: Sep 17 | $7.00 B |
$563.00 M
8.75%
|
| Q2: Jun 17 | $6.94 B |
$492.00 M
7.63%
|
| Q1: Mar 17 | $6.54 B |
$580.00 M
9.73%
|
|
Get instant access to data, Sign up for free
FY 2016
|
$25.64 B |
$2.78 B
12.16%
|
| Q4: Dec 16 | $6.80 B |
$396.00 M
6.19%
|
| Q3: Sep 16 | $6.43 B |
$488.00 M
8.21%
|
| Q2: Jun 16 | $6.45 B |
$977.00 M
17.84%
|
| Q1: Mar 16 | $5.96 B |
$918.00 M
18.21%
|
Agilent Technologies Revenue
Eli Lilly and Company Revenue
Stryker Corporation Revenue
Johnson & Johnson Revenue
Merck & Co. Revenue
Thermo Fisher Scientific Revenue
Abbott Laboratories Revenue
Danaher Corporation Revenue
Amgen Revenue
